Fenwick represented T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, in its $110 Million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors, including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners.
T-knife will use the funds to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T). More information can be obtained from the company's announcement.
The Fenwick transaction team was led by corporate partners Effie Toshav and Ryan Slunaker and associates Andrew Murphy and Sam Millang.